NCT01400698View on ClinicalTrials.gov

Saizen in Intra-uterine Growth Retardation

PHASE3CompletedINTERVENTIONAL
Enrollment

91

Participants

Timeline

Start Date

November 30, 1998

Primary Completion Date

February 28, 2010

Study Completion Date

February 28, 2010

Conditions
Children Born With Serious Intra-uterine Growth Retardation
Interventions
DRUG

Saizen® A

Continuous or intermittent treatment with recombinant human Growth Hormone (r-hGH) 0.067 milligram/kilogram/day (mg/kg/day) subcutaneously (sc).

DRUG

Saizen® B

Observed until the first signs of puberty and then continuous treatment with r-hGH 0.067 mg/kg/day sc or observed without treatment.

OTHER

Observation only

Subjects were only observed.

All Listed Sponsors
collaborator

Merck Serono S.A., Geneva

INDUSTRY

lead

Merck KGaA, Darmstadt, Germany

INDUSTRY

NCT01400698 - Saizen in Intra-uterine Growth Retardation | Biotech Hunter | Biotech Hunter